NCT04943848 2026-03-17
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Recruiting
Clinical Trials
76 trialsNCT05155332 2026-03-17
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
NCT07472153 2026-03-16
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT07090148 2026-03-11
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
Phase 1 Recruiting
NCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06114940 2026-03-05
PLUTO
Jinling Hospital, China
Phase 2 Terminated
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT03983057 2026-02-11
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Zhejiang University
Phase 2 Completed
NCT02964078 2026-02-10
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07392320 2026-02-06
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05223231 2026-02-02
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT06281405 2026-01-27
TORCH-iTNT
Fudan University
Phase 2 Recruiting
NCT07365592 2026-01-26
Neo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT03891953 2026-01-21
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis
Phase 1 Active not recruiting
NCT06468280 2026-01-21
ROSETTE
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06475300 2026-01-21
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT06265727 2026-01-08
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT07318636 2026-01-06
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 1 Not yet recruiting
NCT04146298 2025-12-24
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Changhai Hospital
Phase 1/2 Recruiting
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT07288034 2025-12-17
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07277842 2025-12-11
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06493240 2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2 Completed
NCT05631899 2025-11-24
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT07245901 2025-11-24
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Not yet recruiting
NCT02936102 2025-11-14
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT04058756 2025-10-07
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase 1 Active not recruiting
NCT04544111 2025-10-07
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04000529 2025-09-30
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
Phase 1 Terminated
NCT06008054 2025-09-26
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT03961971 2025-09-10
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06512207 2025-09-09
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Jinzhou Medical University
Phase NA Recruiting
NCT07007182 2025-09-05
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT06255223 2025-09-03
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
Phase 2 Recruiting
NCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT04191421 2025-08-22
Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Emory University
Phase 1/2 Completed
NCT06425926 2025-08-21
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
Phase 1/2 Recruiting
NCT06547957 2025-08-13
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Active not recruiting
NCT04028245 2025-08-07
SPARC-1
Columbia University
Phase EARLY_PHASE1 Active not recruiting
NCT04572451 2025-08-01
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Phase 1 Recruiting
NCT03104699 2025-07-30
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus Inc.
Phase 1/2 Completed
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT06377111 2025-07-14
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
Phase 1 Recruiting
NCT05751928 2025-07-08
NEO-MIMAJOR
Biocad
Phase 3 Active not recruiting